Washington College of Law logo
 
American University logo
The Program on Information Justice and Intellectual Property
Research and Advocacy Resources for Students

Novartis Lawsuit Against India

In 2006, an Indian court ruled that imatinib mesylate, sold by Novartis as Glivec in India, is not patentable under India's patent law, because it is a new form of a known substance. Novartis responded by taking the nation of India to court, charging that its revised patent law violates its international commitments under the WTO TRIPS Agreement, as well as the Indian Constitution. Health advocates fear that a success for Novartis will limit the availability of future generic medicines from India - which is currently a major supplier of generic drugs for the world's poor. On August 6, 2007, the Madras High Court rejected Novartis' challenge of the Indian patent law. The company announced that it is unlikely to appeal the ruling.

Text of the Madras High Court Judgement

 

PIJIP Documents and Events

 

Novartis Documents

 

Government Documents

 

Civil Society Analysis

 

Open Letters to Novartis

 

Related Case

 

 
Washington College of Law  -  4801 Massachusetts Avenue, NW  -  Washington, DC 20016  -  202-274-4000